These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 21250971

  • 1. Optimal management of β thalassaemia intermedia.
    Taher AT, Musallam KM, Cappellini MD, Weatherall DJ.
    Br J Haematol; 2011 Mar; 152(5):512-23. PubMed ID: 21250971
    [Abstract] [Full Text] [Related]

  • 2. Insight onto the pathophysiology and clinical complications of thalassemia intermedia.
    Cappellini MD, Musallam KM, Taher AT.
    Hemoglobin; 2009 Mar; 33 Suppl 1():S145-59. PubMed ID: 20001620
    [Abstract] [Full Text] [Related]

  • 3. Contemporary approaches to treatment of beta-thalassemia intermedia.
    Taher AT, Musallam KM, Karimi M, Cappellini MD.
    Blood Rev; 2012 Apr; 26 Suppl 1():S24-7. PubMed ID: 22631038
    [Abstract] [Full Text] [Related]

  • 4. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
    Taher A, Hershko C, Cappellini MD.
    Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
    [Abstract] [Full Text] [Related]

  • 5. Revisiting beta thalassemia intermedia: past, present, and future prospects.
    Ben Salah N, Bou-Fakhredin R, Mellouli F, Taher AT.
    Hematology; 2017 Dec; 22(10):607-616. PubMed ID: 28589785
    [Abstract] [Full Text] [Related]

  • 6. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
    Ho PJ, Tay L, Lindeman R, Catley L, Bowden DK.
    Intern Med J; 2011 Jul; 41(7):516-24. PubMed ID: 21615659
    [Abstract] [Full Text] [Related]

  • 7. Modern treatment of thalassaemia intermedia.
    Borgna-Pignatti C.
    Br J Haematol; 2007 Aug; 138(3):291-304. PubMed ID: 17565568
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Current management of thalassemia intermedia].
    Thuret I.
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Iron overload in β-thalassemia intermedia: an emerging concern.
    Musallam KM, Cappellini MD, Taher AT.
    Curr Opin Hematol; 2013 May 01; 20(3):187-92. PubMed ID: 23426199
    [Abstract] [Full Text] [Related]

  • 18. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
    Chauhan W, Shoaib S, Fatma R, Zaka-Ur-Rab Z, Afzal M.
    Br J Clin Pharmacol; 2022 Aug 01; 88(8):3610-3626. PubMed ID: 35373382
    [Abstract] [Full Text] [Related]

  • 19. Common queries in thalassemia care.
    Panigrahi I, Marwaha RK.
    Indian Pediatr; 2006 Jun 01; 43(6):513-8. PubMed ID: 16820660
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.